IDEAS home Printed from https://ideas.repec.org/a/nat/nature/v586y2020i7830d10.1038_s41586-020-2814-7.html
   My bibliography  Save this article

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

Author

Listed:
  • Ugur Sahin

    (BioNTech
    TRON gGmbH–Translational Oncology at the University Medical Center of the Johannes Gutenberg)

  • Alexander Muik

    (BioNTech)

  • Evelyna Derhovanessian

    (BioNTech)

  • Isabel Vogler

    (BioNTech)

  • Lena M. Kranz

    (BioNTech)

  • Mathias Vormehr

    (BioNTech)

  • Alina Baum

    (Regeneron Pharmaceuticals)

  • Kristen Pascal

    (Regeneron Pharmaceuticals)

  • Jasmin Quandt

    (BioNTech)

  • Daniel Maurus

    (BioNTech)

  • Sebastian Brachtendorf

    (BioNTech)

  • Verena Lörks

    (BioNTech)

  • Julian Sikorski

    (BioNTech)

  • Rolf Hilker

    (BioNTech)

  • Dirk Becker

    (BioNTech)

  • Ann-Kathrin Eller

    (BioNTech)

  • Jan Grützner

    (BioNTech)

  • Carsten Boesler

    (BioNTech)

  • Corinna Rosenbaum

    (BioNTech)

  • Marie-Cristine Kühnle

    (BioNTech)

  • Ulrich Luxemburger

    (BioNTech)

  • Alexandra Kemmer-Brück

    (BioNTech)

  • David Langer

    (BioNTech)

  • Martin Bexon

    (Bexon Clinical Consulting)

  • Stefanie Bolte

    (BioNTech)

  • Katalin Karikó

    (BioNTech)

  • Tania Palanche

    (BioNTech)

  • Boris Fischer

    (BioNTech)

  • Armin Schultz

    (CRS Clinical Research Services Mannheim GmbH)

  • Pei-Yong Shi

    (University of Texas Medical Branch)

  • Camila Fontes-Garfias

    (University of Texas Medical Branch)

  • John L. Perez

    (Pfizer)

  • Kena A. Swanson

    (Pfizer)

  • Jakob Loschko

    (Pfizer)

  • Ingrid L. Scully

    (Pfizer)

  • Mark Cutler

    (Pfizer)

  • Warren Kalina

    (Pfizer)

  • Christos A. Kyratsous

    (Regeneron Pharmaceuticals)

  • David Cooper

    (Pfizer)

  • Philip R. Dormitzer

    (Pfizer)

  • Kathrin U. Jansen

    (Pfizer)

  • Özlem Türeci

    (BioNTech)

Abstract

An effective vaccine is needed to halt the spread of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic. Recently, we reported safety, tolerability and antibody response data from an ongoing placebo-controlled, observer-blinded phase I/II coronavirus disease 2019 (COVID-19) vaccine trial with BNT162b1, a lipid nanoparticle-formulated nucleoside-modified mRNA that encodes the receptor binding domain (RBD) of the SARS-CoV-2 spike protein1. Here we present antibody and T cell responses after vaccination with BNT162b1 from a second, non-randomized open-label phase I/II trial in healthy adults, 18–55 years of age. Two doses of 1–50 μg of BNT162b1 elicited robust CD4+ and CD8+ T cell responses and strong antibody responses, with RBD-binding IgG concentrations clearly above those seen in serum from a cohort of individuals who had recovered from COVID-19. Geometric mean titres of SARS-CoV-2 serum-neutralizing antibodies on day 43 were 0.7-fold (1-μg dose) to 3.5-fold (50-μg dose) those of the recovered individuals. Immune sera broadly neutralized pseudoviruses with diverse SARS-CoV-2 spike variants. Most participants had T helper type 1 (TH1)-skewed T cell immune responses with RBD-specific CD8+ and CD4+ T cell expansion. Interferon-γ was produced by a large fraction of RBD-specific CD8+ and CD4+ T cells. The robust RBD-specific antibody, T cell and favourable cytokine responses induced by the BNT162b1 mRNA vaccine suggest that it has the potential to protect against COVID-19 through multiple beneficial mechanisms.

Suggested Citation

  • Ugur Sahin & Alexander Muik & Evelyna Derhovanessian & Isabel Vogler & Lena M. Kranz & Mathias Vormehr & Alina Baum & Kristen Pascal & Jasmin Quandt & Daniel Maurus & Sebastian Brachtendorf & Verena L, 2020. "COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses," Nature, Nature, vol. 586(7830), pages 594-599, October.
  • Handle: RePEc:nat:nature:v:586:y:2020:i:7830:d:10.1038_s41586-020-2814-7
    DOI: 10.1038/s41586-020-2814-7
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41586-020-2814-7
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    File URL: https://libkey.io/10.1038/s41586-020-2814-7?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Robert J. Fischer & Neeltje van Doremalen & Danielle R. Adney & Claude Kwe Yinda & Julia R. Port & Myndi G. Holbrook & Jonathan E. Schulz & Brandi N. Williamson & Tina Thomas & Kent Barbian & Sarah L., 2021. "ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7," Nature Communications, Nature, vol. 12(1), pages 1-11, December.
    2. David G. Priest & Takeshi Ebihara & Janyerkye Tulyeu & Jonas N. Søndergaard & Shuhei Sakakibara & Fuminori Sugihara & Shunichiro Nakao & Yuki Togami & Jumpei Yoshimura & Hiroshi Ito & Shinya Onishi & , 2024. "Atypical and non-classical CD45RBlo memory B cells are the majority of circulating SARS-CoV-2 specific B cells following mRNA vaccination or COVID-19," Nature Communications, Nature, vol. 15(1), pages 1-21, December.
    3. Xiaoqi Yu & Dong Wei & Wenxin Xu & Chuanmiao Liu & Wentian Guo & Xinxin Li & Wei Tan & Leshan Liu & Xinxin Zhang & Jieming Qu & Zhitao Yang & Erzhen Chen, 2022. "Neutralizing activity of BBIBP-CorV vaccine-elicited sera against Beta, Delta and other SARS-CoV-2 variants of concern," Nature Communications, Nature, vol. 13(1), pages 1-10, December.
    4. Laurent Renia & Yun Shan Goh & Angeline Rouers & Nina Bert & Wan Ni Chia & Jean-Marc Chavatte & Siew‐Wai Fong & Zi Wei Chang & Nicole Ziyi Zhuo & Matthew Zirui Tay & Yi-Hao Chan & Chee Wah Tan & Nicho, 2022. "Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose," Nature Communications, Nature, vol. 13(1), pages 1-16, December.
    5. Seongryong Kim & Ji Hyang Jeon & Myeonghwan Kim & Yeji Lee & Yun-Ho Hwang & Myungsun Park & C. Han Li & Taeyoung Lee & Jung-Ah Lee & You-Me Kim & Dokeun Kim & Hyukjin Lee & You-Jin Kim & V. Narry Kim , 2024. "Innate immune responses against mRNA vaccine promote cellular immunity through IFN-β at the injection site," Nature Communications, Nature, vol. 15(1), pages 1-15, December.
    6. Sun Jin Kim & Zhong Yao & Morgan C. Marsh & Debra M. Eckert & Michael S. Kay & Anna Lyakisheva & Maria Pasic & Aiyush Bansal & Chaim Birnboim & Prabhat Jha & Yannick Galipeau & Marc-André Langlois & J, 2022. "Homogeneous surrogate virus neutralization assay to rapidly assess neutralization activity of anti-SARS-CoV-2 antibodies," Nature Communications, Nature, vol. 13(1), pages 1-9, December.
    7. Miwa Haranaka & James Baber & Yoichiro Ogama & Masako Yamaji & Masakazu Aizawa & Osamu Kogawara & Ingrid Scully & Eleni Lagkadinou & Ӧzlem Türeci & Uğur Şahin & Philip R. Dormitzer & William C. Gruber, 2021. "A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults," Nature Communications, Nature, vol. 12(1), pages 1-7, December.
    8. Kevin J. Kramer & Erin M. Wilfong & Kelsey Voss & Sierra M. Barone & Andrea R. Shiakolas & Nagarajan Raju & Caroline E. Roe & Naveenchandra Suryadevara & Lauren M. Walker & Steven C. Wall & Ariana Pau, 2022. "Single-cell profiling of the antigen-specific response to BNT162b2 SARS-CoV-2 RNA vaccine," Nature Communications, Nature, vol. 13(1), pages 1-20, December.
    9. Nozomi Kuse & Yu Zhang & Takayuki Chikata & Hung The Nguyen & Shinichi Oka & Hiroyuki Gatanaga & Masafumi Takiguchi, 2022. "Long-term memory CD8+ T cells specific for SARS-CoV-2 in individuals who received the BNT162b2 mRNA vaccine," Nature Communications, Nature, vol. 13(1), pages 1-11, December.
    10. Lena Jaki & Sebastian Weigang & Lisa Kern & Stefanie Kramme & Antoni G. Wrobel & Andrea B. Grawitz & Philipp Nawrath & Stephen R. Martin & Theo Dähne & Julius Beer & Miriam Disch & Philipp Kolb & Lisa, 2023. "Total escape of SARS-CoV-2 from dual monoclonal antibody therapy in an immunocompromised patient," Nature Communications, Nature, vol. 14(1), pages 1-14, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:586:y:2020:i:7830:d:10.1038_s41586-020-2814-7. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.